About: http://data.cimple.eu/news-article/42709615e17d2d22f2100ad61a545763ce516cb41f59a1788ea3f5aa

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/42709615e17d2d22f2100ad61a545763ce516cb41f59a1788ea3f5aa Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US biotech firm Moderna said Wednesday that doses of its new Covid-19 vaccine candidate aimed at the South African coronavirus variant had been shipped to the US National Institutes of Health for testing. "We look forward to beginning the clinical study of our variant booster and are grateful for the NIH's continued collaboration to combat this pandemic," said CEO Stephane Bancel. The South African variant is considered among the more dangerous of current mutations because it evades some of the blocking action of antibodies that target the older coronavirus strain. That means people who were infected with the classic strain are more susceptible to reinfection, and research has also shown the variant has partly reduced the protection of the current generation of vaccines. While initial testing has shown that Moderna's original vaccine -- called mRNA-1273 -- remains effective against emerging variants, the company said it was pursuing the development of a variant-specific vaccine as part of a number of strategies being considered. Either a South Africa variant-specific candidate, called mRNA-1273.351, could be used as a booster, or the company might use a booster that combines the classic vaccine with the variant-specific mRNA-1273.351 to create a new product. Another idea is that people could receive a third dose of the classic vaccine to raise their overall immunity. Moderna is also looking at the possibility of using the South Africa variant-specific mRNA-1273.351 or the combination shot as the primary dose. The US Food and Drug Administration announced Monday that drug makers developing variant-specific vaccines wouldn't need to go through the same lengthy authorization process they had to for their original shots. Moderna also announced it was raising its global manufacturing capacity and would be able to produce up to 1.4 billion doses of its vaccine in 2022 if needed. Additionally, it said it was increasing its plan for 2021 manufacturing from 600 million doses to 700 million doses globally. Moderna has so far shipped 60 million doses, 55 million within the US. ia/to
schema:headline	Moderna S. Africa variant-specific vaccine ready for testing: company
schema:mentions	National Institutes of Health Antibody Ia (cuneiform) Immune system Africa Messenger RNA South Africa Chief executive officer Pandemic Vaccine Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 »more»
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-02-24 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	81 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software